Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03036904 · ClinicalTrials.gov registry record · Phase 1
Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas
A Phase 1 study, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT03036904 is a Phase 1 study that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 31 participants.
The verdict
NCT03036904, a Phase 1 study, has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
This is a phase I, open label, single-arm, multi-center, dose-finding study of venetoclax in combination with DA-EPOCH-R in patients with aggressive B-Cell Lymphomas.
Interventions
- DRUG Venetoclax
- DRUG Cyclophosphamide
- DRUG Rituximab
- DRUG Etoposide
- DRUG Vincristine Sulfate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2017-02-06 |
| Est. Completion | 2021-11-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03036904
The ClinicalTrials.gov registry entry for NCT03036904 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Venetoclax is the first listed.
NCT03036904 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03036904 about?
NCT03036904 is a clinical study titled "Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas". This is a phase I, open label, single-arm, multi-center, dose-finding study of venetoclax in combination with DA-EPOCH-R in patients with aggressive B-Cell Lymphomas.
What is the current status of trial NCT03036904?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2017-02-06. Estimated completion is 2021-11-11.
What interventions are being tested in trial NCT03036904?
The interventions under investigation include: Venetoclax (DRUG), Cyclophosphamide (DRUG), Rituximab (DRUG), Etoposide (DRUG), Vincristine Sulfate (DRUG).
Who is sponsoring clinical trial NCT03036904?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.